Their study revealed for the first time the molecular mechanism of regorafenib resistance in HCC, suggesting that Pin1 inhibitors will be an alternative treatment class for the treatment of aggressive and regorafenib-resistant HCC (Wang et al., 2019). The gene discussed is PIN1; the disease is hepatocellular carcinoma.